Literature DB >> 7933097

Long-term promoter activity during herpes simplex virus latency.

J R Lokensgard1, D C Bloom, A T Dobson, L T Feldman.   

Abstract

The ability to direct foreign gene expression from the herpes simplex virus type 1 (HSV-1) genome during an acute or latent infection is a subject of increasing importance in the utilization of HSV vectors for gene therapy. Little is known about the types of transcription factors present in neurons or about whether different neuronal populations within a ganglion vary in their complement of these factors. With respect to HSV-1 latency, it is not known how or why the latency-associated transcript (LAT) promoter is able to function continually during latency while all other viral promoters are inactive. To further studies of these two phenomena, we constructed seven recombinant viruses with various promoter constructs driving expression of the lacZ reporter gene. Each construct was inserted into HSV-1 at the glycoprotein C locus, and recombinant viruses were evaluated for the ability to express beta-galactosidase during acute and latent viral infections in murine dorsal root ganglia. During acute infection of murine dorsal root ganglia, the activities of the promoters varied over a wide range. Constructs containing the murine metallothionein promoter (MT1), the phosphoglycerate kinase promoter, the Moloney murine leukemia virus long terminal repeat (LTR), or the region upstream of and including the HSV LAT core promoter (LAT) were active during the acute but not the latent phase of infection. The addition of transcription factor binding sites present in the upstream LAT region to the MT1 and LTR promoters (LAT-MT1 and LAT-LTR, respectively) significantly increased acute-phase expression. Despite these high initial rates of transcription, of all the promoter constructs only LAT-LTR was able to remain transcriptionally active after the establishment of a latent state. Thus, the Moloney murine leukemia virus LTR provides a DNA element which functions to prevent promoter inactivation during latency. An analogous HSV long-term-expression element is evidently not present in the upstream LAT promoter, indicating that the HSV long-term-expression function is provided by a region outside of that which gives high-level neuronal expression during the acute phase of infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933097      PMCID: PMC237154     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1.

Authors:  D L Rock; A B Nesburn; H Ghiasi; J Ong; T L Lewis; J R Lokensgard; S L Wechsler
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization.

Authors:  K D Croen; J M Ostrove; L J Dragovic; J E Smialek; S E Straus
Journal:  N Engl J Med       Date:  1987-12-03       Impact factor: 91.245

3.  Detection of herpes simplex virus type 1 transcripts during latent infection in mice.

Authors:  J G Spivack; N W Fraser
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons.

Authors:  J G Stevens; E K Wagner; G B Devi-Rao; M L Cook; L T Feldman
Journal:  Science       Date:  1987-02-27       Impact factor: 47.728

Review 5.  An inquiry into the mechanisms of herpes simplex virus latency.

Authors:  B Roizman; A E Sears
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

6.  Physical characterization of the herpes simplex virus latency-associated transcript in neurons.

Authors:  E K Wagner; G Devi-Rao; L T Feldman; A T Dobson; Y F Zhang; W M Flanagan; J G Stevens
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

7.  RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice.

Authors:  A M Deatly; J G Spivack; E Lavi; N W Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Structure of mouse metallothionein-I gene and its mRNA.

Authors:  N Glanville; D M Durnam; R D Palmiter
Journal:  Nature       Date:  1981-07-16       Impact factor: 49.962

9.  Effect of the transcription start region of the herpes simplex virus type 1 latency-associated transcript promoter on expression of productively infected neurons in vivo.

Authors:  M J Farrell; T P Margolis; W A Gomes; L T Feldman
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter.

Authors:  C N Adra; P H Boer; M W McBurney
Journal:  Gene       Date:  1987       Impact factor: 3.688

View more
  30 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

Authors:  J A Palmer; R H Branston; C E Lilley; M J Robinson; F Groutsi; J Smith; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus.

Authors:  J R Lokensgard; S Hu; W Sheng; M vanOijen; D Cox; M C Cheeran; P K Peterson
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

Review 4.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 5.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 6.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

7.  The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency independently of LAT transcription.

Authors:  Nicole J Kubat; Antonio L Amelio; Nicole V Giordani; David C Bloom
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 8.  Gene therapy for inherited retinal degeneration.

Authors:  R R Ali; M B Reichel; D M Hunt; S S Bhattacharya
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

Review 9.  Replication-defective herpes simplex virus vectors for gene transfer in vivo.

Authors:  P Marconi; D Krisky; T Oligino; P L Poliani; R Ramakrishnan; W F Goins; D J Fink; J C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

10.  Involvement of a high-mobility-group protein in the transcriptional activity of herpes simplex virus latency-active promoter 2.

Authors:  S W French; M C Schmidt; J C Glorioso
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.